Patients with heart failure (HF) and reduced ejection fraction (HFrEF) in Asia exhibit many differences from those in other parts of the world. The purpose of this case is to investigate the efficacy and safety of dapagliflozin, compared with placebo, in HFrEF patients in Asia, compared to those elsewhere, enrolled in the DAPA-HF trial.

JACC: Asia Editor-in-Chief 
Jian’an Wang, MD, PhD, FACC

CME Editor 
Kenneth A. Ellenbogen, MD

Authors
Kieran F. Docherty, MB ChB
John J.V. McMurray, MD

Important Dates

Date of Release: April 19, 2022
Term of Approval/Date of CME/MOC/ECME Expiration: April 18, 2023